Abundnz exhibiting at EPIC Conference

Abundnz will jointly exhibit with ImmunoSYS at the European Partnering and Investment Conference (EPIC) Biotech Conference 2014 in London on 2 October 2014.


New service: SPR imaging

Abundnz now offers label-free profiling of (bio)molecular interactions using Surface Plasmon Resonance imaging technology or SPR imaging (Ibis Technologies B.V.). Applications include epitope mapping, binding studies of an analyte to its ligand, binning of antibodies for blocking epitopes and monitoring complex diseases.


Meet Abundnz at “Knowledge for Growth 2014”

Abundnz will be exhibiting at “Knowledge for Growth 2014” in Gent (Belgium).  “Knowledge for Growth” is Europe’s leading regional life sciences convention. You can meet us at booth 66.


New collaboration with AtoZ-CRO

AtoZ-CRO GmbH from Germany and Abundnz B.V. will work in partnership for phase 0 micro dose studies. AtoZ-CRO is a full-service Clinical Research Organization with over 30 years of experience in Phase I – IV clinical studies.

Other partnerships with Abundnz.

Abundnz has partnerships with ImMunoSysLtd, IBIS Technologies, MsMetrix, Van Sonsbeek Software, InnoTherapy and Ducares.

Contact us for more information


Partnership with InnoTherapy

InnoTherapy Inc. of South Korea and Abundnz have agreed to work in partnership. Both companies’ technologies perfectly fit together. The partnership will offer value proposition to the end users in that InnoTherapy‘s technology can be used to make bio-betters and that Abundnz’ technology can be used to evaluate the pharmacokinetics of such drugs.

InnoTherapy’s Site Specific PEGylation (SEGTM)

Our Selective PEGylation Technology Platform renews the future biosimilar and new drugs
The PEGylation technology has been used for many years to extend half life of small proteins or
nucleic acid based drugs. It is basically attaching PolyEthelyne Glycol (PEG) to a protein
molecule via covalent bond. Though it is a great technology, its major short coming is that it
targets ε-amine of the protein at random, which can easily disrupt active sites of the protein,
rendering it inactive. In addition, it can easily result in heterogeneity of target protein molecules.
At Innotherapy, our technology solves these issues by selectively conjugating PEG to the Nterminal
of the protein molecules, thus creating mono-PEGylation of the target protein and
achieving homogeneity of the drug compounds. Although Aldehyde based PEGylation does
create similar end results, its dependence on harsh chemical treatment and acidic pH may pose
another level of technological issues in final products. Our PEGylation is not only selective on
putting the PEG on the N-term only, but also can produce higher yield through less disruptive
chemical steps. Its usage in EPO and G-CSF alone can create multi Billion dollar block buster
drugs and can be used to new protein based drugs. Thus our platform technology can be applied
to a wide range of potential and existing drug molecules for bio-better or bio-similar markets.
Innotherapy seeks strategic partners who intend to apply our new PEGylation technology
platform to develop either a new drug or bio-better existing drugs. After successful results, we
are interested in various deal structure such as licensing, supplier relationship, or even sell the
technology in one lump sum.

Other partnerships with Abundnz.

Abundnz has partnerships with ImMunoSysLtd, IBIS Technologies, MsMetrix, Van Sonsbeek Software, InnoTherapy and Ducares.


Abundnz interviewed at Biomedica Summit 2013

Abundnz was interviewed by the Enterprise European Network (EEN) at the Biomedica Summit in Aachen, Germany in June this year. The interview was done jointly with our partner ImmunoSYS Ltd., a UK based consulting group specialised in life sciences.

The interview can be viewed here on Vimeo.


Abundnz presents latest results pAMS technology at ASMS 2013

Abundnz will present their latest results about their innovative pAMS technology at ASMS 2013 in Minneapolis (USA).


Abundnz highlighted in Dutch magazine about drug research

In the first edition of 2013 of the Dutch magazine Medicines, special attention is paid to Abundnz and its innovative pAMS technology. Medicines is an independent journal writing about drug research in the Netherlands.

 


Biopharma UK

Abundnz and UK based company ImmunoSYS have agreed to work in partnership to further develop and commercialise our pAMS technology. The tool originally developed by Abundnz is expected to offer drug discovery companies an advanced and better analysis option.

Abundnz has partnerships with ImMunoSysLtd, IBIS Technologies, MsMetrix, Van Sonsbeek Software, InnoTherapy and Ducares.


Happy New Year

Abundnz wishes all their relations a very Happy New Year! We look forward to continue our collaborations with you.